Lyra Therapeutics (LYRA) Competitors $6.64 +0.22 (+3.43%) Closing price 04:00 PM EasternExtended Trading$6.65 +0.01 (+0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. TMDIF, CTCX, ECOR, RBOT, POCI, CLGN, COCH, VVOS, STRR, and PETVShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Titan Medical (TMDIF), Carmell (CTCX), electroCore (ECOR), Vicarious Surgical (RBOT), Precision Optics (POCI), CollPlant Biotechnologies (CLGN), Envoy Medical (COCH), Vivos Therapeutics (VVOS), Star Equity (STRR), and PetVivo (PETV). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. Its Competitors Titan Medical Carmell electroCore Vicarious Surgical Precision Optics CollPlant Biotechnologies Envoy Medical Vivos Therapeutics Star Equity PetVivo Lyra Therapeutics (NASDAQ:LYRA) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends. Is LYRA or TMDIF more profitable? Titan Medical has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,043.64%. Titan Medical's return on equity of -82.31% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-5,043.64% -404.56% -60.06% Titan Medical N/A -82.31%-51.47% Which has higher valuation and earnings, LYRA or TMDIF? Titan Medical has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.53M7.12-$93.43M-$29.01-0.23Titan Medical$17.63M2.24$6.95M$0.056.92 Which has more risk and volatility, LYRA or TMDIF? Lyra Therapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Do institutionals and insiders hold more shares of LYRA or TMDIF? 95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor LYRA or TMDIF? In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score. Company Overall Sentiment Lyra Therapeutics Neutral Titan Medical Neutral Do analysts recommend LYRA or TMDIF? Lyra Therapeutics presently has a consensus price target of $100.00, indicating a potential upside of 1,406.02%. Given Lyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Titan Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTitan Medical beats Lyra Therapeutics on 7 of the 13 factors compared between the two stocks. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.56M$2.56B$5.77B$10.52BDividend YieldN/A53.63%5.53%4.57%P/E Ratio-0.2323.4076.4326.62Price / Sales7.12650.07535.41119.74Price / CashN/A171.0137.4661.85Price / Book0.755.3813.616.45Net Income-$93.43M$32.95M$3.29B$271.57M7 Day Performance4.08%3.68%1.67%2.83%1 Month Performance-9.43%4.89%4.05%7.27%1 Year Performance-51.34%1.22%80.70%26.07% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics2.6778 of 5 stars$6.64+3.4%$100.00+1,406.0%-54.5%$10.56M$1.53M-0.2350TMDIFTitan MedicalN/A$0.36flatN/A+740.0%$41.28M$17.63M-0.2950CTCXCarmellN/A$1.92-17.4%N/A+118.2%$40.05M$32.84K0.0014ECORelectroCore2.2843 of 5 stars$4.83+1.9%$25.50+428.0%-19.2%$35.95M$25.18M-2.9850News CoverageRBOTVicarious Surgical1.7267 of 5 stars$5.85+0.5%$7.00+19.7%+3.2%$34.52MN/A-0.58210News CoverageGap UpPOCIPrecision OpticsN/A$4.39-0.5%N/A-26.4%$33.77M$19.10M-4.9380Positive NewsUpcoming EarningsCLGNCollPlant Biotechnologies2.1908 of 5 stars$2.63+0.4%$11.50+337.3%-46.0%$33.32M$2.40M-2.3370COCHEnvoy Medical2.0003 of 5 stars$1.33+3.1%$9.25+595.5%-73.0%$27.76M$220K-0.9334News CoverageVVOSVivos Therapeutics2.4741 of 5 stars$3.38-2.6%$4.92+45.5%+9.7%$26.04M$15.03M-2.01160Positive NewsSTRRStar Equity1.0558 of 5 stars$9.81+4.7%$5.00-49.0%+151.9%$25.82M$140.06M-7.551,300News CoverageAnalyst RevisionGap UpPETVPetVivoN/A$0.95+5.9%N/A+86.5%$25.11M$1.05M-2.1220 Related Companies and Tools Related Companies TMDIF Competitors CTCX Competitors ECOR Competitors RBOT Competitors POCI Competitors CLGN Competitors COCH Competitors VVOS Competitors STRR Competitors PETV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYRA Stock Alerts